TAVR: Balloon-Expandable or Self-Expanding Valves, Which Is the Answer?

Courtesy of Dr. Carlos Fava.

Transcatheter aortic valve replacement (TAVR) has shown benefit and is currently moving towards low-risk patients, as well as bicuspid aortic valves and (to a lower extent) aortic regurgitation.

Buscando la profundidad óptima para las prótesis autoexpandibles

However, we must ponder on which valve should be used on each patient: balloon-expandable (BE) or self-expanding (SE) valve? They represent different technologies with different stents, release methods, and leaflet characteristics, which translate into differences as regards functioning, hemodynamic profile, and complications.

The CHOICE trial randomized 241 high-risk patients with severe aortic stenosis to receive Edwards SAPIEN XT (121 patients) or CoreValve (120 patients).

Groups were similar: the mean age was 81 years, the Society of Thoracic Surgeons (STS) score was 6, and the EuroSCORElog was 14.

After 5 years of follow-up, there were no significant differences as regards cardiovascular mortality (31.6% for BE vs. 21.5% for SE; p = 0.12), all-cause mortality (53.4% vs. 47.6%; p = 0.38), stroke (17.5% vs. 16.5%; p = 0.73), and readmission due to heart failure (28.9% vs. 22.5%; p = 0.75), infarction, major bleeding, or vascular complications.


Read also: Should We Finalize TAVR with Atrial Pacing in Some Patients?


The need for pacemaker implantation was higher among patients with SE valve (40.4% vs. 25.4%; p = 0.01).

As regards the hemodynamic profile, SE patients had larger prosthetic aortic valve area (1.6 ± 0.5 cm2 vs. 1.9 ± 0.5 cm2; p = 0.02) and a lower gradient (12.2 ± 8.7 mm Hg vs. 6.9 ± 2.7 mm Hg; p = 0.001), without any differences in regurgitation. Clinical valve thrombosis and moderate to severe valve deterioration were higher among BE patients (7.3% vs. 0.8%; p = 0.006, and 6.6% vs. 0%; p = 0.0018). The rate of bioprosthetic valve failure was extremely low, without differences between valves (4.1% vs. 3.4%; p = 0.63).

Conclusion

After a five-year follow-up, patients in the CHOICE trial show that the clinical evolution after transfemoral transcatheter aortic valve replacement with early-generation balloon-expandable and with self-expanding valves is not statistically significantly different. The hemodynamic profile was significantly better with self-expanding valves. Structural valve deterioration was uncommon but occurred more frequent with balloon-expandable valves.

Courtesy of Dr. Carlos Fava.

Original Title: 5-Year Outcomes After TAVR With Balloon-Expandable Versus Self-Expanding Valves Results. From the CHOICE Randomized Clinical Trial.

Reference: Mohamed Abdel-Wahab, et al,. J Am Coll Cardiol Intv 2020;13:1071–82.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Prospective Analysis of the Feasibility of the PASCAL System for Transcatheter Mitral Repair: OneForAll Registry

Courtesy of Dr. Juan Manuel Pérez. Mitral transcatheter edge-to-edge repair (M-TEER) is an effective option for patients with severe mitral regurgitation who are at high...

Left Bundle Branch Block after TAVR: What Is Its Impact?

Courtesy of Dr. Juan Manuel Pérez. Left bundle branch block (LBBB) is a common complication following transcatheter aortic valve replacement (TAVR), which can be either...

Multicenter Experience with 3D Intracardiac Echocardiography for Guiding Interventional Cardiac Procedures

Courtesy of Dr. Juan Manuel Pérez. Imaging techniques play a fundamental role in interventional cardiac procedures. Intracardiac echocardiography (ICE) appears as an alternative to transesophageal...

Pathology of Self-Expanding Transcatheter Aortic Bioprostheses and Hypoattenuated Leaflet Thickening

Courtesy of Dr. Juan Manuel Pérez. Despite the available long term followup data on of transcatheter aortic valve replacement (TAVR), bioprosthesis durability continues under debate....

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...